Ozmosi | Cobicistat Drug Profile

Product Description

Cobicistat is used to increase the amounts of atazanavir (Reyataz, in Evotaz ) in adults and children weighing at least 77 pounds (35 kg) or darunavir (Prezista, in Prezcobix ) in adults and children weighing at least 88 pounds (40 kg) in the blood when these medications are used to treat human immunodeficiency virus (HIV). Cobicistat is in a class of medications called pharmacokinetic boosters. It works by increasing the amount of atazanavir or darunavir in the body so that they can have a greater effect. (Sourced from: https://medlineplus.gov/druginfo/meds/a616029.html)

Mechanisms of Action: Integrase Inhibitor, CYP3A4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: Western America
Company CEO: Daniel P. O’Day
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cobicistat

Countries in Clinic: Australia, Belgium, France, Germany, Ireland, Italy, Spain, United Kingdom, United States

Active Clinical Trial Count: 7

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Acquired Immunodeficiency Syndrome|COVID-19|HIV Infections

Phase 1: Healthy Volunteers|Kidney Diseases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT03696160	LAPTOP	P3	Completed	Acquired Immunodeficiency Syndrome\|HIV Infections	2024-06-17	33%	2024-09-20	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2020-001031-27	Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention	P3	Active, not recruiting	COVID-19	2020-06-13		2025-05-25	Treatments
ACTRN12621000745842p	2006-7041-83/hah	P1	Not yet recruiting	Kidney Diseases	2022-02-28
2015-000313-40	2015-000313-40	P3	Completed	HIV Infections	2024-05-25		2025-05-25	Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
ACTRN12619001607167p	2006-7041-83/hah	P1	Not yet recruiting	Healthy Volunteers	None
NCT06385119	F8394-101	P1	Completed	Healthy Volunteers	2024-12-22	50%	2025-08-27	Primary Endpoints\|Treatments
2021-000738-32	2021-000738-32	P1	Active, not recruiting	HIV Infections	2023-03-15	14%

Recent News Events

Date	Type	Title
02/10/2026	News Article	Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
01/21/2026	News Article	Johnson & Johnson reports Q4 and Full-Year 2025 results
10/30/2025	News Article	Gilead Sciences Announces Third Quarter 2025 Financial Results
10/14/2025	News Article	Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Cobicistat

Alternative Names: cobicistat, tybost, evotaz, prezcobix, stribild, symtuza Clinical Status: Inactive Latest Update: 2026-02-10 Latest Update Note: News Article